Trial Profile
A Phase I Trial of High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 27 May 2023
Price :
$35
*
At a glance
- Drugs Anti-CD19 CAR-transduced T cells (Primary) ; Carmustine; Cytarabine; Etoposide; Melphalan; Pegfilgrastim
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- 02 May 2023 Planned End Date changed from 1 Apr 2023 to 1 Apr 2024.
- 02 May 2023 Planned primary completion date changed from 1 Apr 2023 to 1 Apr 2024.
- 05 Apr 2022 Planned End Date changed from 1 Apr 2022 to 1 Apr 2023.